Global Nonvenereal Syphilis Treatment Market Highlights over 2022 – 2030

The global nonvenereal syphilis treatment market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022 – 2030. Non-venereal syphilis, also known as bejel, is an endemic caused by the same bacteria that causes syphilis. The growth of the market can be attributed to the increasing prevalence and awareness regarding non-venereal syphilis. This syphilis is not transmitted sexually, however, it can be transmitted orally, from mouth to mouth, or by sharing utensils. The bacteria treponema pallidum infects the skin and tissues, especially the mucosa layer inside the nose and mouth, resulting in callus, patch, or abscess on the face. The severe symptoms include lesions on the face, limbs, head, or testicles, and inflammation, along with infection that may spread to the bones and internal tissues. The growing incidences of bejel, is estimated to boost the market growth. According to the statistics of Center of Disease Control and Prevention, 129,813 cases of all stages of syphilis, were reported in 2019, globally. As per the data by World Health Organization, over 80,000 cases of bejel are reported each year. Moreover, the increasing demand for treatment, backed by the rapid pace of infection transmission, is estimated to boost the market growth.

Get more information on this report: Download Sample PDF

The global nonvenereal syphilis treatment market is segmented by treatment into antibiotics, topical treatment, and others, out of which, the antibiotics segment is anticipated to hold the notable share in the market over the forecast period on account of easy availability of broad-spectrum antibiotics, such as, penicillin, and fast overall action of the drug. Moreover, antibiotics can kill the infection from its root cause and provide lost-lasting relief. This is estimated to boost the segment growth. 

Major Macro-Economic Indicators Impacting the Market Growth

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Nonvenereal Syphilis Treatment Market Regional Synopsis

On the basis of geographical analysis, the global nonvenereal syphilis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East and Africa region is estimated to witness noteworthy growth over the forecast period on the back of high prevalence of nonvenereal syphilis in regions of west Africa, Mediterranean, and Sahara. Lack of sanitization, hot and humid climate, and lack of proper healthcare services in the region, are estimated to boost the market growth.

The market in the Asia Pacific region is anticipated to gain the largest market share throughout the forecast period owing to the growing cases of bejel in underdeveloped areas of the APAC region, including, Nepal, Myanmar, Cambodia, Bangladesh, and parts of India.

Get more information on this report: Download Sample PDF

The global nonvenereal syphilis treatment market is further classified on the basis of region as follows:

• North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
• Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global nonvenereal syphilis treatment market includes the following segments:

By Diagnosis

• Lesions Testing
• Dark-Field Microscopy 
• Others

By Treatment

• Antibiotics
• Topical Treatment

Growth Drivers

• Increasing Prevalence of Nonvenereal Syphilis or Bejel
• Rising Demand for Treatment of Syphilis

Challenges

• Lack of Proper Healthcare System in Low-Income Regions

Top Featured Companies Dominating the Market

• Pfizer, Inc.
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Novartis International AG
• Sanofi S.A.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Otsuka Pharmaceutical Co., Ltd.,
• Abbott Laboratories
• Cipla Limited